DAYTONA BEACH, Fla., Sept. 23, 2020 – The Ladies Professional Golf Association (LPGA) today announced that Eurofins has been named the Tour’s Official Testing Partner. Eurofins, a world leader in clinical diagnostics, forensic, pharmaceutical, food and environmental laboratory testing services, will leverage the Eurofins SAFER@WORKTM protocols to aid in the Tour’s continued safe return to play. The partnership, slated to run through 2021, will ensure the LPGA has an easy, painless, fast and reliable COVID-19 testing program.
“The health and safety of our athletes, caddies, staff and tournament partners is always our number one priority, and it was very important for us to find a global testing partner that would help fit our needs in the United States and internationally. As a world-wide leader in bio-analysis, Eurofins is a perfect match for our global Tour and schedule,” said Heather Daly-Donofrio, LPGA Chief Tour Operations Officer. “We are excited to welcome Eurofins to the LPGA family as we work to maintain a safe and healthy tournament environment each week on Tour.”
Players, caddies, staff and essential personnel will take self-administered, mid-nasal polymerase chain reaction (PCR) tests at an on-site testing location upon tournament arrival. Direct pathogen detection via PCR is the industry method of choice to detect acute COVID-19 infection. Eurofins will leverage its global network of laboratories to offer the LPGA a dedicated on-site team to monitor sample collection at each tournament and provide results within 24-48 hours.
Eurofins has been at the forefront of COVID-19 testing – launching its first RT-PCR (real-time reverse-transcriptase polymerase chain reaction) assay for SARS-CoV-2 on March 13. Since then, Eurofins has rolled out several highly accurate, FDA-approved active infection and antibody assays to thousands of clients nationwide, including hospitals, physicians’ offices, nursing homes, government entities, sports organizations and employers. In addition to individual PCR testing, Eurofins offers a robust group of assays for COVID-19, including pooled, antibody, wastewater, worn-mask, and environmental surfaces and will soon be launching saliva testing.